[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472483":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":32,"locations":41,"responsibleParty":61,"collaborators":31,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":31,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":31,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Acer Therapeutics Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ACER-002 (celiprolol) 200 mg BID","EXPERIMENTAL","ACER-002 200 mg twice daily (BID) (after titration):\n\n200 mg morning and 200 mg evening: 400 mg total daily dose\n\nTitration:\n\nDay 1 to Month 1 - 100 mg once daily (QD) evening: 100 mg total daily dose Month 2 to Month 3 - 100 mg morning and 100 mg evening: 200 mg total daily dose Month 3 to Month 4 - 100 mg morning and 200 mg evening: 300 mg total daily dose Month 4 to End of Treatment Period (BID) - 200 mg morning and 200 mg evening: 400 mg total daily dose",[13],"Drug: ACER-002 (celiprolol) 200 mg BID",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo BID","Placebo twice daily (BID) Placebo given orally to mimic ACER-002 (celiprolol) administration",[18],"Drug: Placebo BID",[20,26],{"type":21,"name":9,"description":9,"armGroupLabels":22,"otherNames":23},"DRUG",[9],[24,25],"ACER-002","celiprolol",{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"placebo for ACER-002",[15],[30],"placebo",null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Sheila Woodhouse, MD; Ph.D.","CONTACT","984-377-3737","sheila.woodhouse@science37.com",{"name":39,"role":35,"phone":36,"phoneExt":31,"email":40},"Jonathan Cotliar, MD; Ph.D.","jonathan@science37.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Science 37","RECRUITING","Culver City","California","90230","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-118.39647,34.02112,{"lat":54,"lon":53},[57,59],{"name":58,"role":35,"phone":36,"phoneExt":31,"email":37},"Sheila Woodhouse, MD",{"name":60,"role":35,"phone":36,"phoneExt":31,"email":40},"Johnathan Cotliar, MD",{"type":62,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100472483","phase-3-clinical-trial-to-compare-the-efficacy-of-celiprolol-to-placebo-in-patients-with-vascular-ehlers-danlos-syndrome-100472483",false,"NCT05432466","Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome","A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome","DiSCOVER","Inclusion Criteria:\n\n1. Willingness to obtain magnetic resonance angiogram (MRA) image at local imaging facility.\n2. A genetic test confirming the presence of a pathogenic COL3A1 variant (classified as likely pathogenic or pathogenic according to ACMG\u002FAMP Guidelines.\n3. Patients must be ≥ 15 years of age at the time of randomization.\n4. Able and willing to discontinue use of β-blockers prior to randomization.\n\nExclusion Criteria:\n\n1. Lack of a COL3A1-positive test at screening (e.g., COL3A1 benign, likely benign, variant of unknown significance \\[VUS\\] or no variant) or presence of a COL3A1 variant but demonstration of a COL3A1 variant reported to be a haploinsufficiency variant.\n2. Arterial rupture or dissection, uterine rupture, and\u002For intestinal rupture within 6 months prior to Screening.\n3. Patients unable to discontinue β-blocker treatment prior to randomization.\n4. Unable or unwilling to complete the study procedures.\n5. Breastfeeding, pregnancy, or planned pregnancy during the trial.\n6. Any medical condition that in the opinion of the Investigator may pose a safety risk to the patient in this study, which may confound efficacy or safety assessment, or may interfere with study participation.\n7. Use of any prohibited medications","ALL","15 Years","64 Years",{"count":75,"type":76},150,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.",[82],"Vascular Ehlers-Danlos Syndrome","2025-08-19",{"date":85,"type":86},"2025-08-24","ACTUAL",{"date":88,"type":86},"2022-11-07",{"date":90,"type":76},"2029-04-01",{"name":5,"class":6},1]